Publication:
Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy

dc.contributor.buuauthorÖzkan, Hasan Atilla
dc.contributor.buuauthorHakyemez, Bahattin
dc.contributor.buuauthorÖzkalemkaş, Fahir
dc.contributor.buuauthorAli, Rıdvan
dc.contributor.buuauthorÖzkocaman, Vildan
dc.contributor.buuauthorÖzçelik, Tülay
dc.contributor.buuauthorTaşkapılıoğlu, Özlem
dc.contributor.buuauthorAltundal, Yıldız
dc.contributor.buuauthorTunalı, Ayfer
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.departmentRadyoloji Ana Bilim Dalı
dc.contributor.departmentNöroloji Ana Bilim Dalı
dc.contributor.orcid0000-0002-3425-0740
dc.contributor.researcheridX-3647-2018
dc.contributor.researcheridAAI-2318-2021
dc.contributor.researcheridAAG-8495-2021
dc.contributor.researcheridAAH-1854-2021
dc.contributor.scopusid9250698600
dc.contributor.scopusid6602527239
dc.contributor.scopusid6601912387
dc.contributor.scopusid7201813027
dc.contributor.scopusid6603145040
dc.contributor.scopusid7005424333
dc.contributor.scopusid23037226400
dc.contributor.scopusid15080726300
dc.contributor.scopusid6602797853
dc.date.accessioned2021-11-18T06:39:00Z
dc.date.available2021-11-18T06:39:00Z
dc.date.issued2006
dc.description.abstractIntroduction Reversible posterior leukoencephalopathy syndrome (RPLS) is a recently described clinical and radiological entity comprising headache, seizures, altered level of consciousness and visual disturbances in association with transient posterior cerebral white-matter abnormalities. Method We report a young woman with Burkitt's lymphoma who developed RPLS after combined chemotherapy administered during the tumor lysis syndrome. Results The symptoms in this patient fitted well with those of RPLS; they included abrupt alterations in mental status, seizures, headache, visual changes and characteristic neuroradiological findings. She was given further combination chemotherapy without any neurological complications, at which time she had already recovered from both RPLS and tumor lysis syndrome. Conclusion Although many etiological factors have been reported in the development of RPLS, the underlying mechanism is not yet well understood. With prompt and appropriate management, RPLS is usually reversible, and chemotherapy can be continued after complete recovery from RPLS. We suggest that tumor lysis syndrome should be considered as a contributory factor to the development of RPLS in patients for whom treatment with combined chemotherapy for hematological malignancies is planned.
dc.identifier.citationÖzkan, A. vd. (2006). ''Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy''. Neuroradiology, 48(12), 887-892.
dc.identifier.endpage892
dc.identifier.issn0028-3940
dc.identifier.issn1432-1920
dc.identifier.issue12
dc.identifier.pubmed16983525
dc.identifier.scopus2-s2.0-33751536932
dc.identifier.startpage887
dc.identifier.urihttps://doi.org/10.1007/s00234-006-0142-8
dc.identifier.urihttps://link.springer.com/article/10.1007/s00234-006-0142-8
dc.identifier.urihttp://hdl.handle.net/11452/22706
dc.identifier.volume48
dc.identifier.wos000242365500004
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherSpringer
dc.relation.journalNeuroradiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectNeurosciences & neurology
dc.subjectRadiology, nuclear medicine & medical imaging
dc.subjectTumor lysis syndrome
dc.subjectReversible posterior leukoencephalopathy syndrome
dc.subjectMRI
dc.subjectChemotherapy
dc.subjectLeukemia
dc.subjectLymphoma
dc.subjectVasospasm
dc.subjectPatient
dc.subjectCombination chemotherapy
dc.subjectEncephalopathy syndrome
dc.subject.emtreeVincristine
dc.subject.emtreePhenytoin
dc.subject.emtreeMethotrexate
dc.subject.emtreeDoxorubicin
dc.subject.emtreeDexamethasone
dc.subject.emtreeCytarabine
dc.subject.emtreeCyclophosphamide
dc.subject.emtreeCorticosteroid
dc.subject.emtreeAllopurinol
dc.subject.emtreeWeight reduction
dc.subject.emtreeVomiting
dc.subject.emtreeTumor lysis syndrome
dc.subject.emtreeTonic clonic seizure
dc.subject.emtreeRisk factor
dc.subject.emtreeReversible posterior leukoencephalopathy syndrome
dc.subject.emtreeRehydration
dc.subject.emtreePriority journal
dc.subject.emtreePathogenesis
dc.subject.emtreeNausea; nuclear magnetic resonance imaging
dc.subject.emtreeLeukoencephalopathy
dc.subject.emtreeHuman
dc.subject.emtreeHospital admission
dc.subject.emtreeHeadache
dc.subject.emtreeGrand mal seizure
dc.subject.emtreeFollow up
dc.subject.emtreeFemale
dc.subject.emtreeComputer assisted tomography
dc.subject.emtreeComa
dc.subject.emtreeCase report
dc.subject.emtreeCancer combination chemotherapy
dc.subject.emtreeBurkitt iymphoma
dc.subject.emtreeBlurred vision
dc.subject.emtreeArticle
dc.subject.emtreeAdult
dc.subject.emtreeAbdominal pain
dc.subject.meshTumor lysis syndrome
dc.subject.meshSyndrome
dc.subject.meshSeizures
dc.subject.meshMagnetic resonance imaging
dc.subject.meshHypertensive encephalopathy
dc.subject.meshHumans
dc.subject.meshHeadache
dc.subject.meshFemale
dc.subject.meshFatal outcome
dc.subject.meshComa
dc.subject.meshBurkitt lymphoma
dc.subject.meshBlindness, cortical
dc.subject.meshAntineoplastic combined chemotherapy protocols
dc.subject.scopusPosterior Reversible Encephalopathy Syndrome; Eclampsia; Hypertension Encephalopathy
dc.subject.wosClinical neurology
dc.subject.wosNeuroimaging
dc.subject.wosRadiology, nuclear medicine & medical imaging
dc.titleTumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy
dc.typeArticle
dc.wos.quartileQ2 (Neuroimaging)
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Radyoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Nöroloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: